Tag: Mammalian

Cell Expansion Market Worth $39.7 Billion By 2027

The global cell expansion market size is expected to reach USD 39.7 billion by 2027 registering a CAGR of 9.4%, according to a new report by Grand View Research, Inc. Cell expansion techniques are increasingly employed for the development of cellular and gene therapies from a single cord blood collection. These techniques can also be used for the expansion of stored Stem Cells (SCs) for the development of cancer therapies. Therefore, significant developments in cord blood SCs expansion technologies are expected to boost market growth.

Companies have made heavy investments for the expansion of tissue-engineered products and the development of biologics. For instance, in March 2019, Merck KGaA invested USD 168 million for the expansion of its biologics manufacturing facility in Switzerland. Such initiatives are expected to boost the demand for solutions required for biologic development, thereby leading to market growth.

Bioreactors are fundamental tools in this market. Extensive research studies related to the applications of bioreactor engineering approaches have led to the incorporation of novel culture technologies. Moreover, the combined use of automated bioreactors with the microcarrier technology leads to an efficient expansion and enrichment of the cancer SCs. As a result, these approaches have gained immense traction in this market.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/cell-expansion-market

Further key findings from the report suggest:

  • Broad portfolio of automated expansion systems along with improvements in bioreactor design for large-scale bioproduction results in the lucrative growth opportunity for instruments
  • The microbial cells segment is expected to witness the fastest growth rate owing to the implementation of high-throughput cultivation approaches and techniques that avoid the formation of biofilms
  • Biopharmaceuticals segment held the largest revenue share in 2019 due to growth in the demand for biosimilars, continuous R&D investments in biomanufacturing, and rise in the number of approvals for biologics
  • Asia Pacific is anticipated to grow at the maximum CAGR from 2020 to 2027 due to presence of several consortiums that focus on the evolving fields in the biomedical industry
  • For instance, in November 2019, the Cell & Gene Therapy Asia 2019 held in Japan focused on the evolving field of SCs for their deployment in pharmaceutical discovery and cellular therapies

Cell Line Development Market To Reach $6.24 Billion By 2022

Global cell line development market size is expected to reach USD 6.24 billion by 2022, according to a new report by Grand View Research, Inc. The Increasing demand for monoclonal antibodies and patent expiration of blockbuster biologics are expected to drive the cell line development industry over the forecast period.

Increasing prevalence of autoimmune diseases and cancer are likely to increase the demand for accurate and cost effective treatment options which is expected to render a positive impact on market growth. In addition, improving healthcare infrastructure, economic development and favorable government initiatives promoting the growth of the biotechnology industry are factors contributing towards the growth of the cell line development market.

Ongoing R&D for stable & authentic cell lines and the introduction of technologically advanced processes such as single use bioreactor and micro bioreactor for large scale bioproduction are further expected to provide this market with lucrative future growth opportunities.

To request a sample copy:
http://www.grandviewresearch.com/industry-analysis/cell-line-development-market

Further key findings from the study suggest:

  • Reagent and media was the largest product market in 2014, owing to increasing number of cell culture procedures. Reagent and media are necessary components involved in cell line development procedures & cell culture and are cost intensive in nature. The market for reagent and media was valued at over 1.0 billion in 2014.
  • Mammalian cell lines were widely used as a source for cell line development in 2014, owing to associated advantages such as accurate complex protein expression nature, critical for the production of monoclonal antibodies, vaccines, and biologics.
  • Cell line development finds the largest application in the bioproduction of biologics, vaccines, Mabs, therapeutic proteins and biosimilars. Rising demand for monoclonal antibodies and vaccines are expected to boost the growth of this segment over the forecast period. The market for cell line development based bioproduction is also expected to witness lucrative growth of over 12.5% during the forecast period.
  • North America was the largest market in 2014, with revenue estimated at over 800 million. The region’s market dominance is attributed to factors such as the growing adoption rates of cell culture techniques, presence of well-developed healthcare infrastructure, supportive government initiatives and high healthcare expenditure levels.
  • Asia Pacific cell line development market is anticipated to register rapid growth over the forecast period owing to factors such as the presence of high unmet needs, rising number of CROs (Contract Research Organization) providing pertinent services, growing R&D investments aimed at the development of stable cell lines and increasing biologics production.
  • Key players in this market include European Collection of cell Cultures (ECACC), Lonza Group AG, GE Healthcare, Thermo Fisher Scientific Inc., Sartorious AG, Selexis SA, Wuxi AppTec Inc., Sigma-Aldrich Corporation, American Type Culture Collection (ATCC) and Corning Inc.